Current Report · Items 2.02, 8.01, 9.01 · 8-K

Perspective Therapeutics, Inc.

CATXNYSE_AMERICANEQUITYCurrent

Results of Operations and Financial Condition · Other Events

Filed Aug 10, 2026Accepted Aug 10, 2026, 4:30 PM EDTCIK 728387Accession 0001193125-26-342495

Company context

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, creating an opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

Current securities

CATXNYSE_AMERICAN · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On August 10, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and providing recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Form 8-K”) and is incorporated by reference into this Item 2.02. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 8.01Item 8.01 - Other Events

Item 8.01 Other Events. Also on August 10, 2026, the Company posted an updated corporate presentation to its website at www.perspectivetherapeutics.com. A copy of the presentation is filed as Exhibit 99.2 to this Form 8-K and is incorporated by reference into this Item 8.01. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 99.1 Press release issued by Perspective Therapeutics, Inc., dated August 10, 2026. 99.2 Corporate presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

Filed exhibits (2)

EX-99.1 (by filename) catx-ex99_1.htm

EX-99.1 2 catx-ex99_1.htm EX-99.1 EX-99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results • Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback; sufficient isotope access and manufacturing capacity • VMT-α-NET study update accepted for oral presentation at ESMO 2026 • VMT01 melanoma and PSV359 FAP-α clinical programs continue to advance • Approximately $237 million in cash, cash equivalents, and short-term investments as of June 30, 2026; expected to be sufficient to fund current planned clinical milestones and operational investments into late 2027 SEATTLE - August 10, 2026 - Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended June 30, 2026. “The team at Perspective is highly energized as we continue to build on the significant cli…

Open exhibit ↗

EX-99.2 (by filename) catx-ex99_2.htm

EX-99.2 3 catx-ex99_2.htm EX-99.2 Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Engineering the Alpha Advantage in Targeted Oncology Unlocking New Treatment Options Across Solid Tumors: Optimizing the Entire System Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals Optimizing Structural Chemistry: Choosing the Right Isotope Not All ²¹²Pb Programs Are Created Equal Advancing a Theranostic Approach: Solid Tumors are an Attractive Market for Radiopharmaceuticals Expanding the Addressable Market Direct-to-Hospital Delivery through Integrated Isotope Production Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product Reaching the Largest Addressable Market with Regional Manufacturing Advancing a Diverse 212Pb-Based Oncology Portfolio SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need VMT-α-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2 Ongoing Phase 1/2a to Establish Broad Therapeutic Window for VMT-α-NET VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 …